Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies
Complete Title: A Phase 1/2, Multi-center, Open-Label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positivie Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Trial Phase: I/II
Investigator: Roland Walter, MD
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and preliminary anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is currently enrolling eligible AML, BPDCN and ALL patients.
Keywords:
- Leukemia, Acute Myeloid (AML)
- Leukemia
- Leukemia, Lymphoid
- Myelodysplastic-Myeloproliferative Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
I/II
Roland Walter, MD
RG1005597
NCT03386513
A Phase 1/2, Multi-center, Open-Label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positivie Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Leukemia, Acute Myeloid (AML)
Leukemia
Leukemia, Lymphoid
Myelodysplastic-Myeloproliferative Diseases